INSM Nov 2024 30.000 call
| Previous close | 8.80 |
| Open | 8.70 |
| Bid | 27.00 |
| Ask | 31.00 |
| Strike | 30.00 |
| Expiry date | 2024-11-15 |
| Day's range | 8.70 - 8.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 16 |
PR NewswireInsmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Monday, June 10, 2024, at 10:00 a.m. ET.
- PR Newswire
Insmed to Host Commercial Webinar on June 4, 2024
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, will host a commercial webinar on Tuesday, June 4, 2024, at 8:00 a.m. ET to discuss the market outlook for the Company's three most advanced programs, ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP).
- PR Newswire
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it priced an underwritten public offering of 12,621,359 shares of its common stock at a price to the public of $51.50 per share. The gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, are expected to be approximately $650 million. I
